40914-11-2

Basic information

• Product Name: 2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE
• Synonyms: OTAVA-BB BB7020410086;AKOS BBS-00006515;2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE;CHEMBRDG-BB 9071028;2-chloro-N-(cyclohexylmethyl)acetamide(SALTDATA: FREE)
• CAS NO: 40914-11-2
• Molecular Formula: C₉H₁₆ClNO
• Molecular Weight: 189.68
• Mol File: 40914-11-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 337.5°C at 760 mmHg
• Flash Point: 157.9°C
• Appearance: /
• Density: 1.066g/cm³
• Vapor Pressure: 0.000104mmHg at 25°C
• Refractive Index: 1.475
• CAS DataBase Reference: 2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE(40914-11-2)
• EPA Substance Registry System: 2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE(40914-11-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 40914-11-2(Hazardous Substances Data)

Usage

General Description

2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE is a chemical compound with the molecular formula C10H16ClNO. It is a chlorinated derivative of acetamide that contains a cyclohexylmethyl substituent. 2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE is commonly used in the synthesis of pharmaceuticals and agrochemicals due to its versatile reactivity. It is also used in the production of 4-oxo-pentanoic acid derivatives, which have potential biological activities. Additionally, 2-CHLORO-N-(CYCLOHEXYLMETHYL)ACETAMIDE is known for its mild physiological effect and has been explored for its potential as a local anesthetic. Overall, this chemical compound has diverse applications in various industries and fields of research.

InChI:InChI=1/C9H16ClNO/c10-6-9(12)11-7-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,12)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 3218-02-8 cyclohexylmethylamine 

Downstream Products

• 596808-06-9 2-(2-bromopyridin-3-yloxy)-N-cyclohexylmethylacetamide 

Relevant articles and documents

COVALENT TARGETING OF E3 LIGASES

Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.

Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-N,N′,N″, N'''-1,4,7-trisacetic Acid (DO3A) Conjugate of Tranexamates: A Quest for a Liver-specific Magnetic Resonance Imaging Contrast Agent

The work is directed toward the synthesis of a series of DO3A conjugates of tranexamates (1c-e) and their Gd complexes (2c-e) for use as a liver-specific MRI CA. All these complexes show thermodynamic and kinetic stabilities comparable to those of structu

SUBSTITUTED HETEROCYCLIC COMPOUNDS

Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.